Reuters logo
BRIEF-Johnson & Johnson says FDA approved 10 mg dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​
October 30, 2017 / 12:30 PM / 20 days ago

BRIEF-Johnson & Johnson says FDA approved 10 mg dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​

Oct 30 (Reuters) - Johnson & Johnson-

* FDA approves new 10 mg dosing for Xarelto® (rivaroxaban) to reduce the continued risk of venous thromboembolism (VTE)

* Janssen Pharmaceuticals says U.S. FDA approved 10 mg once-daily dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below